Safety and efficacy of incobotulinumtoxinA doses up to 800 U in limb spasticity: The TOWER study

OBJECTIVE: To evaluate safety (primary objective) and efficacy of increasing doses (400 U up to 800 U) of incobotulinumtoxinA (Xeomin, Merz Pharmaceuticals GmbH) for patients with limb spasticity. METHODS: In this prospective, single-arm, dose-titration study (NCT01603459), patients (18–80 years) wi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neurology
Main Authors: Wissel, Jörg, Bensmail, Djamel, Ferreira, Joaquim J., Molteni, Franco, Satkunam, Lalith, Moraleda, Susana, Rekand, Tiina, McGuire, John, Scheschonka, Astrid, Flatau-Baqué, Birgit, Simon, Olivier, Rochford, Edward T.J., Dressler, Dirk, Simpson, David M.
Formato: Artigo
Idioma:Inglês
Publicado em: Lippincott Williams & Wilkins 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5379931/
https://ncbi.nlm.nih.gov/pubmed/28283596
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/WNL.0000000000003789
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
A carregar...

Registos relacionados